News

Under the terms of the agreement Icon will pay initial cash consideration of $35 million. If certain performance milestones are achieved, a further consideration, up to a maximum

Jenny Harry, CEO of Proteome Systems, said: “Over the past few years, the management team has focused on leveraging the company’s core strengths in the validation and development

This transaction is said to expand Valeant’s Australian specialty pharmaceutical business through the acquisition of key products in both the retail and prescription brands, which complement Valeant’s current

Thomas Sandgaard, CEO of Zynex, said: “We are excited to now have a total of four of our products covered by CE marking for sales in Europe.”

Eisai has received a complete response letter for Banzel as an adjunctive treatment for partial-onset seizures with and without secondary generalization in adults and adolescents 12 years of

In the randomized cross-over pilot study, 14 patients were treated before mealtime on three days with three different insulin therapies – regular human insulin (RHI), insulin lispro (90

This new agreement provides the HealthTrust membership access to high quality Hudson RCI products and services, and includes new products designed to maximize clinician efficiency and improve patient

Amlexanox 5% paste and OraDisc A are used for the treatment of canker sores and include the active ingredient amlexanox. OraDisc A is a novel patented mucoadhesive, water-erodible

According to an ADMETRx release, ADMETRx and Roche both recognize how comprehensive data integration may offer significant advantages to discovery groups in selecting candidates for advancement. Phil Burton,